UCSF Mission Bay Conference Center
San Francisco, CA
Wilson Sonsini is proud to sponsor LaunchBio's Invest in Cures, Impact Investing Through Disease Foundations.
Join us on February 12, 2026 at the University of California San Francisco (UCSF) to explore the transformative potential of impact investing in addressing rare disease challenges. This annual forum highlights the promise of venture philanthropy and innovative collaborations, offering hope for the commercialization of therapies that could revolutionize the treatment of rare diseases.
Learn from venture leaders, advocates, researchers, and entrepreneurs as they share insights on accelerating translational research and advancing cures for patients through strategic funding and collaboration. This signature event brings together investment professionals from leading venture philanthropy funds to discuss cutting-edge approaches to supporting and funding breakthrough therapies. It features main-stage sessions, panel discussions, intimate gatherings and high-level networking opportunities.
Full agenda to come.
Katie Stonum
kstonum@wsgr.com
Dr. Laurie McNamara is a partner in the San Diego and San Francisco offices of Wilson Sonsini Goodrich & Rosati, where she focuses her practice on matters related to intellectual property and patent prosecution strategy for early-stage through clinical-stage therapeutics companies. She counsels clients on matters related to global patent portfolio development and strategy, non-infringement, patentability, and freedom-to-operate studies. She advises company clients in connection with major financial transactions such as collaboration agreements, venture financings, merger & acquisitions, and public offerings. In addition to company-side representation, Laurie works with top venture capital firms related to IP diligence of target companies for financings. Laurie has represented venBio, OrbiMed, Logos Capital, Venrock, Foresight Capital, Novo Holdings, Vida Ventures, Avalon BioVentures, Two Bear Capital, and Samsara BioCapital in connection with financings of target companies developing biologics therapeutic programs.